Diversity of Immune Checkpoints in Cancer Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Mar 24

PMID 36960057

Authors

Zhangyan Guo

Rui Zhang

An-Gang Yang

Guoxu Zheng

Affiliations

Soon will be listed here.

Abstract

Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors.

Citing Articles

Pan-Cancer Analysis of ANO6 and Experimental Validation in Metastatic Melanoma.

An Y, Dong H, Yan M, Liu C, Hu D, Liu Q Biochem Genet. 2025; .

PMID: 40042755 DOI: 10.1007/s10528-025-11074-7.

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.

Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A J Immunother Cancer. 2025; 13(1).

PMID: 39824527 PMC: 11749597. DOI: 10.1136/jitc-2024-008876.

Precision medicine in gynecological cancer (Review).

Aravantinou-Fatorou A, Georgakopoulou V, Dimopoulos M, Liontos M Biomed Rep. 2025; 22(3):43.

PMID: 39810899 PMC: 11729136. DOI: 10.3892/br.2025.1921.

Diagnostics and Therapy for Malignant Tumors.

Tsai C, Wang C, Chang H, Chang P, Chang C, Chu T Biomedicines. 2025; 12(12.

PMID: 39767566 PMC: 11726849. DOI: 10.3390/biomedicines12122659.

References

Monney L, Sabatos C, Gaglia J, Ryu A, Waldner H, Chernova T . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415(6871):536-41. DOI: 10.1038/415536a. View

Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C . Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015; 29(2):635-641. DOI: 10.1016/j.intimp.2015.09.017. View

Sakuishi K, Jayaraman P, Behar S, Anderson A, Kuchroo V . Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011; 32(8):345-9. PMC: 3164311. DOI: 10.1016/j.it.2011.05.003. View

Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R . Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021; 6(1):236. PMC: 8219715. DOI: 10.1038/s41392-021-00629-w. View

Macauley M, Crocker P, Paulson J . Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14(10):653-66. PMC: 4191907. DOI: 10.1038/nri3737. View

Weiskopf K, Ring A, Ho C, Volkmer J, Levin A, Volkmer A . Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341(6141):88-91. PMC: 3810306. DOI: 10.1126/science.1238856. View

Viitala M, Virtakoivu R, Tadayon S, Rannikko J, Jalkanen S, Hollmen M . Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8 T-cell Response against Immunosuppressive Tumors. Clin Cancer Res. 2019; 25(11):3289-3303. DOI: 10.1158/1078-0432.CCR-18-3016. View

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Mimura K, Kua L, Xiao J, Asuncion B, Nakayama Y, Syn N . Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. Gastric Cancer. 2021; 24(3):611-623. PMC: 8065004. DOI: 10.1007/s10120-020-01151-8. View

11.

Triebel F, JITSUKAWA S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E . LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5):1393-405. PMC: 2187904. DOI: 10.1084/jem.171.5.1393. View

12.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

13.

Benson Jr D, Bakan C, Zhang S, Collins S, Liang J, Srivastava S . IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011; 118(24):6387-91. PMC: 3490103. DOI: 10.1182/blood-2011-06-360255. View

14.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

15.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

16.

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

17.

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G . Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996; 156(11):4154-9. View

18.

Yang Z, Kim H, Villasboas J, Chen Y, Price-Troska T, Jalali S . Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017; 8(37):61425-61439. PMC: 5617435. DOI: 10.18632/oncotarget.18251. View

19.

Hsu J, Hodgins J, Marathe M, Nicolai C, Bourgeois-Daigneault M, Trevino T . Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018; 128(10):4654-4668. PMC: 6159991. DOI: 10.1172/JCI99317. View

20.

Slovin S, Higano C, Hamid O, Tejwani S, Harzstark A, Alumkal J . Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24(7):1813-1821. PMC: 3707423. DOI: 10.1093/annonc/mdt107. View